Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Amur Minerals ( (GB:CRTX) ) is now available.
CRISM Therapeutics Corporation has successfully raised £1,000,000 through an oversubscribed placing of new ordinary shares, which will fund the progression of its Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma patients. The funds will support various operational and clinical trial costs, with the first patient dosing expected in Q1 2026. The placing reflects strong shareholder support and positions CRISM to advance its innovative cancer treatment technology, potentially impacting its market position and offering new opportunities for stakeholders.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based clinical stage company specializing in the localized and sustained delivery of chemotherapy drugs to improve cancer treatment outcomes. Their lead product, ChemoSeed, is designed to be implanted directly into tumors or resection margins, particularly for glioblastoma, allowing chemotherapy drugs to bypass the blood-brain barrier and effectively target tumor tissues.
Average Trading Volume: 74,298
Technical Sentiment Signal: Sell
Current Market Cap: £4.4M
For a thorough assessment of CRTX stock, go to TipRanks’ Stock Analysis page.